Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)
Telemedicine at the service of patients 🚀
We’re proud to announce a partnership with TeleClinic, Germany’s market leader for online consultations.
Our users in Germany can now consult with a registered practitioner in the country within a few hours, and receive prescriptions and sick notes directly on their smartphones. 📲
Now accessible through Vik Asthma and Vik Neurodermitis in Germany, this partnership represents an important milestone in our mission to empower patients with the best tools throughout their care journey. 🤝 From testing the severity of the disease to accessing HCPs directly through Vik, we’re one step closer to facilitating and shortening the time spent on clinical inertia by chronic disease patients.
After taking Vik Atopic Dermatitis to 9 countries and in four different languages, our main goal remains guiding patients through their search for a healthier life.
We are proud to announce the launch of Vik Colorectal in Spain! Developed with the institutional support of Pierre Fabre Group, our newest virtual companion will support patients and their loved ones living with colorectal cancer!
It’s with great pleasure that we announce our partnership with Maiia, an e-health solution powered by Cegedim Santé! 💪 Bringing to you the news today, Benoit Brouard, founder and CEO of Wefight, and Victor Jobin, Partnerships Director at Maiia.
Vik Atopic Dermatitis continues its expansion across the world! 🚀 It’s been launched in 3 more countries: the United Arab Emirates, the Kingdom of Saudi Arabia, and Brazil!